Flamel Technologies SA (NASDAQ:FLML)’s share price was up 1.9% during trading on Wednesday . The company traded as high as $13.72 and last traded at $13.66, with a volume of 60,900 shares. The stock had previously closed at $13.40.

A number of equities analysts have commented on FLML shares. Leerink Swann reissued a “buy” rating and issued a $16.00 price objective on shares of Flamel Technologies SA in a research note on Tuesday, May 10th. Zacks Investment Research raised Flamel Technologies SA from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Flamel Technologies SA currently has an average rating of “Buy” and a consensus target price of $18.63.

The stock has a market cap of $567.48 million and a price-to-earnings ratio of 33.32. The stock’s 50-day moving average is $12.25 and its 200 day moving average is $10.75.

Flamel Technologies SA (NASDAQ:FLML) last announced its quarterly earnings data on Monday, August 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.06 by $0.08. The company earned $38.90 million during the quarter, compared to analysts’ expectations of $32.80 million. During the same quarter in the previous year, the business earned $0.34 EPS. Flamel Technologies SA’s revenue was down 20.0% compared to the same quarter last year. On average, equities research analysts forecast that Flamel Technologies SA will post ($0.92) EPS for the current fiscal year.

Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.